{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:25:47Z","timestamp":1770747947903,"version":"3.49.0"},"reference-count":12,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":2045,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2006,6]]},"abstract":"<jats:p><jats:italic>Candida<\/jats:italic> esophagitis, a defining illness of acquired immunodeficiency syndrome (AIDS), requires systemic antifungal therapy. <jats:italic>Candida albicans<\/jats:italic> can become resistant to commonly administered azole antifungal agents. An attractive alternative is caspofungin, an echinocandin antifungal that has generally displayed predictable activity against <jats:italic>C. albicans<\/jats:italic>. We report the case of a 29\u2010year\u2010old woman with AIDS who developed recurrent esophagitis caused by a strain of <jats:italic>C. albicans<\/jats:italic> that showed reduced susceptibility to caspofungin (elevated minimum inhibitory concentration of 8 mg\/L). Analysis of the strain revealed that it contained a serine\u2010to\u2010proline substitution at position 645 in the <jats:italic>FKS1<\/jats:italic> gene. Clinicians who prescribe caspofungin to treat esophagitis caused by <jats:italic>C. albicans<\/jats:italic> should recognize the potential risk, albeit slight, for acquired resistance to caspofungin and possibly other echinocandin antifungal agents in the face of persistent disease. In patients who are refractory or unresponsive to caspofungin therapy, susceptibility testing and\/or alternative therapy should be considered.<\/jats:p>","DOI":"10.1592\/phco.26.6.877","type":"journal-article","created":{"date-parts":[[2006,5,22]],"date-time":"2006-05-22T13:14:16Z","timestamp":1148303656000},"page":"877-880","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Progressive Esophagitis Caused by <i>Candida albicans<\/i> with Reduced Susceptibility to Caspofungin"],"prefix":"10.1002","volume":"26","author":[{"given":"Christopher D.","family":"Miller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben W.","family":"Lomaestro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Perlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/380796"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.10.3845-3849.2004"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.2.451-457.2002"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.4.1382-1383.2004"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh548"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.12.5729-5731.2003"},{"key":"e_1_2_1_8_2","volume-title":"NCCLS M27\u2010A2 standards for yeasts: reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard","author":"National Committee for Clinical Laboratory Standards","year":"2002"},{"key":"e_1_2_1_9_2","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1128\/iai.64.8.3244-3251.1996","article-title":"Characterization of echinocandin\u2010resistant mutants of Candida albicans: genetic, biochemical and virulence studies","volume":"64","author":"Kurtz M.B.","year":"1996","journal-title":"Infect Immunol"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.8.3264-3273.2005"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.11.2471"},{"key":"e_1_2_1_12_2","first-page":"2326","article-title":"In vitro preclinical evaluation studies with the echinocandin antifungal MK\u20100091","volume":"41","author":"Bartizal K.","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.3.739-745.2002"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.26.6.877","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.26.6.877","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:32:36Z","timestamp":1761064356000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.26.6.877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["10.1592\/phco.26.6.877"],"URL":"https:\/\/doi.org\/10.1592\/phco.26.6.877","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}